Company profile: Ypsomed
1.1 - Company Overview
Company description
- Provider of injection and infusion systems for self-medication, partnering with pharmaceutical and biotechnology companies for injection pens and autoinjectors. Delivers mylife Diabetescare solutions including infusion systems, blood glucose monitoring and therapy management, the mylife YpsoPump insulin pump, YpsoMate autoinjector, and mylife Loop automated insulin dosing.
Products and services
- YpsoMate: Produces a prefilled-syringe-compatible autoinjector used for self-treatment in various metabolic conditions, supporting patient-administered medication in a safe and simple way
- Ypsomed Delivery Systems: Delivers self-medication-focused injection technologies and services to pharmaceutical and biotechnology companies, covering patient-administered injection pens and autoinjector assemblies for reliable therapy delivery
- Mylife YpsoPump: Constructs an electric-motor-driven insulin pump system with a touchscreen interface for diabetes management, enabling patient self-dosing via controlled infusion
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ypsomed
TheraSense
HQ: United States
Website
- Description: Provider of easy-to-use glucose self-monitoring systems for people with diabetes, using proprietary technologies to dramatically reduce the pain of testing. Products are less painful than current offerings; FreeStyle, the first product, accurately measures glucose levels in blood.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TheraSense company profile →
Lifecare
HQ: Norway
Website
- Description: Provider of miniaturized, implantable glucose sensors and nano biosensing solutions. Offerings include Sencell, a real-time glucose sensor measuring osmotic pressure, lasting at least six months and transmitting data wirelessly to smart devices; NanoBioSensors for high-resolution diagnostics in live tissue; and Lifecare Veterinary for continuous animal glucose monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lifecare company profile →
Imcyse
HQ: Belgium
Website
- Description: Provider of clinical-stage biopharmaceutical R&D, pioneering active specific immunotherapies to treat severe, chronic autoimmune diseases. Its technology platform locally targets immune cells involved in the destruction of diseased organs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imcyse company profile →
Sensulin
HQ: United States
Website
- Description: Provider of diabetes drug discovery focused on a once-a-day glucose-responsive insulin for type 1 and type 2 diabetes, designed to reduce hypoglycemia risk and long-term complications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sensulin company profile →
Diabetomics
HQ: United States
Website
- Description: Provider of non-invasive medical diagnostics for personalized health and diabetes risk, offering point-of-care tests: Glucema saliva test for diabetes monitoring via glycosylated proteins; Lumella blood test for early preeclampsia via glycosylated fibronectin; Insudex for early type-1 diabetes and LADA via autoantibody titers; RAprime for rheumatoid arthritis from oral fluid or finger stick; CovAb oral-swab COVID-19 antibody test detecting IgA/IgM/IgG.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diabetomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ypsomed
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ypsomed
2.2 - Growth funds investing in similar companies to Ypsomed
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ypsomed
4.2 - Public trading comparable groups for Ypsomed
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →